tert-butyl (3R)-3-{[methoxy(methyl)-amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate | 444583-18-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (3R)-3-{[methoxy(methyl)-amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate
• 英文别名: (3R)-tert-butyl 3-(methoxy(methyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate；tert-butyl (3R)-3-[methoxy(methyl)carbamoyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 444583-18-0
• 化学式: C₁₇H₂₄N₂O₄
• 分子量: 320.389
• InChiKey: VCOVIOYPTIKGCS-CQSZACIVSA-N

物化性质

• 沸点：
  421.9±55.0 °C(Predicted)
• 密度：
  1.161±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3R)-3-{[methoxy(methyl)-amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 0.75h， 生成 (R)-3-甲酰基-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯
  参考文献：
  名称：

  AMINOTROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  本发明涉及公式（I）所定义的化合物，这些化合物是黑色素皮质素受体激动剂，以及它们的制备和在治疗和预防肥胖、糖尿病和可能影响两性的性功能障碍，治疗心血管疾病，以及抗炎用途或治疗酒精依赖症中的治疗用途。

  公开号：

  US20070191361A1
• 作为产物：
  描述：

  BOC-D-1,2,3,4-四氢异喹啉-3-羧酸 、 N-甲基-N-甲氧基胺盐酸盐 在 N-甲基吗啉 、 water soluble carbodiimide 、 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 tert-butyl (3R)-3-{[methoxy(methyl)-amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate
  参考文献：
  名称：

  C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors

  摘要：

  Here we report the synthesis and biological properties of peptide-based molecules bearing constrained analogues of phenylalanine at the C-terminal. Compounds were tested as proteasome subunits' inhibitors. Dehydro-peptides showed good inhibition, in particular against trypsin-like (T-L) proteasome activity while some C-terminal Tic-derivatives inhibit only caspase-like activity in enzymatic beta 1 subunits with a certain degree of efficacy. The best analogues of the series demonstrated good resistance to proteolysis and a capacity to permeate the cell membrane. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.10.002

文献信息

• Modulators of serotonin receptors
  申请人：Wacker A. Dean

  公开号：US20050080074A1

  公开（公告）日：2005-04-14

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了血清素受体调节剂，包含这些调节剂的药物组合物以及治疗与血清素受体调节相关的各种疾病、症状和疾患的方法，例如：代谢性疾病，包括但不限于肥胖、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• AMINOTROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BRAUN Alain

  公开号：US20070191361A1

  公开（公告）日：2007-08-16

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及公式（I）所定义的化合物，这些化合物是黑色素皮质素受体激动剂，以及它们的制备和在治疗和预防肥胖、糖尿病和可能影响两性的性功能障碍，治疗心血管疾病，以及抗炎用途或治疗酒精依赖症中的治疗用途。
• [EN] MODULATORS OF SEROTONIN RECEPTORS<br/>[FR] MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005035533A1

  公开（公告）日：2005-04-21

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂、含有这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病症和疾患的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• Piperazine- and piperidine-derivatives as melanocortin receptor agonists
  申请人：——

  公开号：US20040082590A1

  公开（公告）日：2004-04-29

  The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction. 1

  本发明涉及公式I的黑色素细胞激素受体激动剂，其在肥胖症、糖尿病和男性和/或女性性功能障碍的治疗中有用。1
• Melanocortin receptor agonists
  申请人：——

  公开号：US20040092507A1

  公开（公告）日：2004-05-13

  The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction. 1

  本发明涉及公式（I）的黑色素皮质素受体激动剂，其在肥胖症、糖尿病和男性和/或女性性功能障碍的治疗中有用。